MA34713B1 - Compose bicyclique - Google Patents
Compose bicycliqueInfo
- Publication number
- MA34713B1 MA34713B1 MA35965A MA35965A MA34713B1 MA 34713 B1 MA34713 B1 MA 34713B1 MA 35965 A MA35965 A MA 35965A MA 35965 A MA35965 A MA 35965A MA 34713 B1 MA34713 B1 MA 34713B1
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic compound
- present
- compound
- prophylaxis
- obesity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010266097 | 2010-11-30 | ||
| JP2011175330 | 2011-08-10 | ||
| PCT/JP2011/078010 WO2012074126A1 (en) | 2010-11-30 | 2011-11-29 | Bicyclic compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34713B1 true MA34713B1 (fr) | 2013-12-03 |
Family
ID=45418740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35965A MA34713B1 (fr) | 2010-11-30 | 2013-06-05 | Compose bicyclique |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8729102B2 (enExample) |
| EP (1) | EP2649062B1 (enExample) |
| JP (1) | JP5824517B2 (enExample) |
| KR (1) | KR20140001965A (enExample) |
| CN (1) | CN103347872B (enExample) |
| AR (1) | AR084032A1 (enExample) |
| AU (1) | AU2011337565A1 (enExample) |
| BR (1) | BR112013013417A2 (enExample) |
| CA (1) | CA2819400A1 (enExample) |
| CL (1) | CL2013001520A1 (enExample) |
| CO (1) | CO6751239A2 (enExample) |
| CR (1) | CR20130281A (enExample) |
| DO (1) | DOP2013000118A (enExample) |
| EA (1) | EA201390794A1 (enExample) |
| EC (1) | ECSP13012719A (enExample) |
| ES (1) | ES2536319T3 (enExample) |
| MA (1) | MA34713B1 (enExample) |
| MX (1) | MX2013006113A (enExample) |
| PE (1) | PE20140161A1 (enExample) |
| PH (1) | PH12013501099A1 (enExample) |
| SG (1) | SG190925A1 (enExample) |
| TW (1) | TW201242951A (enExample) |
| UY (1) | UY33756A (enExample) |
| WO (1) | WO2012074126A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY33354A (es) | 2010-04-27 | 2011-12-01 | Takeda Pharmaceutical | Compuesto biciclico como inhibidor acc |
| JPWO2013061962A1 (ja) | 2011-10-24 | 2015-04-02 | 武田薬品工業株式会社 | 二環性化合物 |
| EP2928473B1 (en) * | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| PL403149A1 (pl) * | 2013-03-14 | 2014-09-15 | Celon Pharma Spółka Akcyjna | Nowe związki pochodne pirazolilobenzo[d]imidazolu |
| AU2014262636A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| EA201591962A1 (ru) | 2013-05-10 | 2016-06-30 | Нимбус Аполло, Инк. | Ингибиторы акк и их применение |
| AU2014262638A1 (en) * | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| EP2994128B1 (en) | 2013-05-10 | 2019-01-30 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| MX2016002479A (es) | 2013-09-12 | 2016-05-31 | Pfizer | Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris. |
| CN105722841A (zh) | 2013-11-14 | 2016-06-29 | 卡迪拉保健有限公司 | 新型杂环化合物 |
| MY195016A (en) | 2014-08-04 | 2023-01-03 | Nuevolution As | Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases |
| CN104193731B (zh) * | 2014-08-27 | 2017-03-15 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
| HRP20211778T1 (hr) | 2014-08-29 | 2022-03-18 | Chdi Foundation, Inc. | Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina |
| JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| CN104447725B (zh) * | 2014-10-22 | 2018-02-02 | 浙江大学 | 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法 |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| CA2999852A1 (en) * | 2015-09-29 | 2017-04-06 | Oncotherapy Science, Inc. | Bicyclic compound and use thereof for inhibiting suv39h2 |
| CN105601626A (zh) * | 2015-11-04 | 2016-05-25 | 浙江大学 | 一种含2-取代噁唑啉衍生物的制备方法 |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| ES2995198T3 (en) | 2016-01-05 | 2025-02-07 | Incyte Corp | Pyridine compounds as pi3k-gamma inhibitors |
| TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| WO2018200517A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| BR112022012205A2 (pt) | 2019-12-20 | 2022-09-13 | Nuevolution As | Compostos ativos para receptores nucleares |
| CA3174252A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| JPWO2023090411A1 (enExample) | 2021-11-19 | 2023-05-25 | ||
| AR129265A1 (es) | 2022-05-12 | 2024-08-07 | Syngenta Crop Protection Ag | Compuestos de alcoxi-heteroaril-carboxamida o tioamida |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| JP2002501503A (ja) * | 1997-04-30 | 2002-01-15 | イーライ・リリー・アンド・カンパニー | 抗血栓症剤 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| PT1285651E (pt) | 2000-04-28 | 2010-10-21 | Takeda Pharmaceutical | Antagonistas da hormona concentradora da melanina |
| EP1283199A4 (en) | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | MELANINE CONCENTRATING HORMONE ANTAGONISTS |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| EP1542997B1 (en) * | 2002-07-24 | 2012-02-29 | Dermira (Canada), Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| JP5291471B2 (ja) * | 2006-02-15 | 2013-09-18 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| JP5535931B2 (ja) | 2008-10-27 | 2014-07-02 | 武田薬品工業株式会社 | 二環性化合物 |
| US8927576B2 (en) * | 2009-04-06 | 2015-01-06 | PTC Therpeutics, Inc. | HCV inhibitor and therapeutic agent combinations |
| UY33354A (es) | 2010-04-27 | 2011-12-01 | Takeda Pharmaceutical | Compuesto biciclico como inhibidor acc |
| WO2012108478A1 (ja) | 2011-02-09 | 2012-08-16 | 武田薬品工業株式会社 | 単環化合物 |
-
2011
- 2011-11-29 US US13/306,069 patent/US8729102B2/en not_active Expired - Fee Related
- 2011-11-29 PH PH1/2013/501099A patent/PH12013501099A1/en unknown
- 2011-11-29 KR KR1020137016850A patent/KR20140001965A/ko not_active Withdrawn
- 2011-11-29 BR BR112013013417A patent/BR112013013417A2/pt not_active IP Right Cessation
- 2011-11-29 EP EP11802168.2A patent/EP2649062B1/en active Active
- 2011-11-29 EA EA201390794A patent/EA201390794A1/ru unknown
- 2011-11-29 WO PCT/JP2011/078010 patent/WO2012074126A1/en not_active Ceased
- 2011-11-29 AR ARP110104436A patent/AR084032A1/es not_active Application Discontinuation
- 2011-11-29 CA CA2819400A patent/CA2819400A1/en not_active Abandoned
- 2011-11-29 PE PE2013001328A patent/PE20140161A1/es not_active Application Discontinuation
- 2011-11-29 MX MX2013006113A patent/MX2013006113A/es not_active Application Discontinuation
- 2011-11-29 UY UY0001033756A patent/UY33756A/es not_active Application Discontinuation
- 2011-11-29 JP JP2013524677A patent/JP5824517B2/ja not_active Expired - Fee Related
- 2011-11-29 SG SG2013041546A patent/SG190925A1/en unknown
- 2011-11-29 TW TW100143674A patent/TW201242951A/zh unknown
- 2011-11-29 ES ES11802168.2T patent/ES2536319T3/es active Active
- 2011-11-29 AU AU2011337565A patent/AU2011337565A1/en not_active Abandoned
- 2011-11-29 CN CN201180066388.XA patent/CN103347872B/zh not_active Expired - Fee Related
-
2013
- 2013-05-29 CL CL2013001520A patent/CL2013001520A1/es unknown
- 2013-05-29 DO DO2013000118A patent/DOP2013000118A/es unknown
- 2013-06-05 MA MA35965A patent/MA34713B1/fr unknown
- 2013-06-11 CR CR20130281A patent/CR20130281A/es not_active Application Discontinuation
- 2013-06-24 CO CO13149620A patent/CO6751239A2/es not_active Application Discontinuation
- 2013-06-25 EC ECSP13012719 patent/ECSP13012719A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20140161A1 (es) | 2014-02-19 |
| CA2819400A1 (en) | 2012-06-07 |
| CR20130281A (es) | 2013-10-07 |
| JP5824517B2 (ja) | 2015-11-25 |
| WO2012074126A1 (en) | 2012-06-07 |
| CN103347872A (zh) | 2013-10-09 |
| MX2013006113A (es) | 2013-11-01 |
| US8729102B2 (en) | 2014-05-20 |
| AU2011337565A1 (en) | 2013-07-11 |
| TW201242951A (en) | 2012-11-01 |
| US20120142714A1 (en) | 2012-06-07 |
| KR20140001965A (ko) | 2014-01-07 |
| AU2011337565A2 (en) | 2013-07-11 |
| WO2012074126A9 (en) | 2013-06-06 |
| BR112013013417A2 (pt) | 2019-09-24 |
| CN103347872B (zh) | 2014-12-24 |
| DOP2013000118A (es) | 2013-09-30 |
| CL2013001520A1 (es) | 2013-10-18 |
| AR084032A1 (es) | 2013-04-17 |
| ECSP13012719A (es) | 2013-12-31 |
| EP2649062A1 (en) | 2013-10-16 |
| EP2649062B1 (en) | 2015-04-08 |
| SG190925A1 (en) | 2013-07-31 |
| PH12013501099A1 (en) | 2013-07-08 |
| ES2536319T3 (es) | 2015-05-22 |
| EA201390794A1 (ru) | 2013-11-29 |
| CO6751239A2 (es) | 2013-09-16 |
| UY33756A (es) | 2012-06-29 |
| JP2013545718A (ja) | 2013-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35623B1 (fr) | Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives | |
| MA35085B1 (fr) | Procede de traitement d'une nephropathie induite par les produits de contraste | |
| EA201390794A1 (ru) | Бициклическое соединение | |
| MA45940B1 (fr) | Composé hétérocyclique | |
| MA35861B1 (fr) | Inhibiteur de la kinase régulant les signaux de l'apoptose | |
| MA39246A1 (fr) | Composé hétérocyclique fusionné | |
| MA38390A1 (fr) | Composés tétrahydropyrrolothiazines | |
| MA35611B1 (fr) | Composé inhibiteur de la signalisation par la voie notch | |
| WO2018182051A8 (en) | IP6K INHIBITORS | |
| MA32283B1 (fr) | Composes cycliques condenses et utilisation de ceux-ci | |
| MA46337A (fr) | Composé de pyridine | |
| MA31189B1 (fr) | Composés à cycles fusionnés utiles en tant qu'agonistes partiels de ppar-gamma | |
| MA34245B1 (fr) | Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc. | |
| MA35351B1 (fr) | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| MA33280B1 (fr) | Preparation solide | |
| MA34556B1 (fr) | Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger | |
| WO2018194181A8 (en) | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | |
| MA30523B1 (fr) | Compose tricylique et utilisation pharmaceutique de celui-ci | |
| MA37501B1 (fr) | Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1 | |
| MA35030B1 (fr) | Derives pyrdinyl-et pyrazinyl-methyloxy-aryle utiles en tant qu'inhibiteurs de la tyrosine kinase de la rate (syk) | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| EA201170481A1 (ru) | Сокристаллы |